company background image
HZNP

Horizon Therapeutics NasdaqGS:HZNP Stock Report

Last Price

US$89.34

Market Cap

US$20.3b

7D

1.5%

1Y

-5.8%

Updated

19 May, 2022

Data

Company Financials +
HZNP fundamental analysis
Snowflake Score
Valuation3/6
Future Growth5/6
Past Performance5/6
Financial Health5/6
Dividends0/6

HZNP Stock Overview

Horizon Therapeutics Public Limited Company, a biotechnology company, focuses on the discovery, development, and commercialization of medicines that address critical needs for people impacted by rare, autoimmune, and severe inflammatory diseases.

Horizon Therapeutics Competitors

Price History & Performance

Summary of all time highs, changes and price drops for Horizon Therapeutics
Historical stock prices
Current Share PriceUS$89.34
52 Week HighUS$120.54
52 Week LowUS$82.51
Beta1.11
1 Month Change-22.14%
3 Month Change-4.32%
1 Year Change-5.81%
3 Year Change263.17%
5 Year Change796.09%
Change since IPO876.39%

Recent News & Updates

May 09

Horizon: For Those Who Dare

Horizon's inflammation segment is on fire in a not good way. The biopharmaceutical firm's orphan therapies segment presents another, far more interesting opportunity. The company is performing well in a perilous market environment.

Shareholder Returns

HZNPUS BiotechsUS Market
7D1.5%5.7%0.5%
1Y-5.8%-21.4%-11.5%

Return vs Industry: HZNP exceeded the US Biotechs industry which returned -21.4% over the past year.

Return vs Market: HZNP exceeded the US Market which returned -11.5% over the past year.

Price Volatility

Is HZNP's price volatile compared to industry and market?
HZNP volatility
HZNP Average Weekly Movement5.4%
Biotechs Industry Average Movement12.4%
Market Average Movement7.9%
10% most volatile stocks in US Market17.0%
10% least volatile stocks in US Market3.0%

Stable Share Price: HZNP is not significantly more volatile than the rest of US stocks over the past 3 months, typically moving +/- 5% a week.

Volatility Over Time: HZNP's weekly volatility (5%) has been stable over the past year.

About the Company

FoundedEmployeesCEOWebsite
20051,940Tim Walberthttps://www.horizontherapeutics.com

Horizon Therapeutics Public Limited Company, a biotechnology company, focuses on the discovery, development, and commercialization of medicines that address critical needs for people impacted by rare, autoimmune, and severe inflammatory diseases. The company operates in two segments, Orphan and Inflammation. Its portfolio comprises 12 medicines in the areas of rare diseases, gout, ophthalmology, and inflammation.

Horizon Therapeutics Fundamentals Summary

How do Horizon Therapeutics's earnings and revenue compare to its market cap?
HZNP fundamental statistics
Market CapUS$20.33b
Earnings (TTM)US$862.10m
Revenue (TTM)US$3.77b

23.8x

P/E Ratio

5.4x

P/S Ratio

Earnings & Revenue

Key profitability statistics from the latest earnings report
HZNP income statement (TTM)
RevenueUS$3.77b
Cost of RevenueUS$855.34m
Gross ProfitUS$2.91b
Other ExpensesUS$2.05b
EarningsUS$862.10m

Last Reported Earnings

Mar 31, 2022

Next Earnings Date

n/a

Earnings per share (EPS)3.75
Gross Margin77.31%
Net Profit Margin22.87%
Debt/Equity Ratio53.3%

How did HZNP perform over the long term?

See historical performance and comparison

Valuation

Is Horizon Therapeutics undervalued compared to its fair value and its price relative to the market?

Valuation Score

3/6

Valuation Score 3/6

  • Below Fair Value

  • Significantly Below Fair Value

  • PE vs Industry

  • PE vs Market

  • PEG Ratio

  • PB vs Industry


>50%

Undervalued compared to fair value

Share Price vs. Fair Value

Below Fair Value: HZNP ($89.34) is trading below our estimate of fair value ($275.62)

Significantly Below Fair Value: HZNP is trading below fair value by more than 20%.


Price To Earnings Ratio

PE vs Industry: HZNP is poor value based on its PE Ratio (23.8x) compared to the US Biotechs industry average (14.6x).

PE vs Market: HZNP is poor value based on its PE Ratio (23.8x) compared to the US market (15.5x).


Price to Earnings Growth Ratio

PEG Ratio: HZNP is good value based on its PEG Ratio (0.9x)


Price to Book Ratio

PB vs Industry: HZNP is overvalued based on its PB Ratio (4.3x) compared to the US Biotechs industry average (1.5x).


Future Growth

How is Horizon Therapeutics forecast to perform in the next 1 to 3 years based on estimates from 12 analysts?

Future Growth Score

5/6

Future Growth Score 5/6

  • Earnings vs Savings Rate

  • Earnings vs Market

  • High Growth Earnings

  • Revenue vs Market

  • High Growth Revenue

  • Future ROE


27.7%

Forecasted annual earnings growth

Earnings and Revenue Growth Forecasts


Analyst Future Growth Forecasts

Earnings vs Savings Rate: HZNP's forecast earnings growth (27.7% per year) is above the savings rate (1.9%).

Earnings vs Market: HZNP's earnings (27.7% per year) are forecast to grow faster than the US market (12.4% per year).

High Growth Earnings: earnings are expected to grow significantly over the next 3 years.

Revenue vs Market: HZNP's revenue (11.8% per year) is forecast to grow faster than the US market (7.8% per year).

High Growth Revenue: HZNP's revenue (11.8% per year) is forecast to grow slower than 20% per year.


Earnings per Share Growth Forecasts


Future Return on Equity

Future ROE: HZNP's Return on Equity is forecast to be high in 3 years time (22.6%)


Past Performance

How has Horizon Therapeutics performed over the past 5 years?

Past Performance Score

5/6

Past Performance Score 5/6

  • Quality Earnings

  • Growing Profit Margin

  • Earnings Trend

  • Accelerating Growth

  • Earnings vs Industry

  • High ROE


64.0%

Historical annual earnings growth

Earnings and Revenue History

Quality Earnings: HZNP has high quality earnings.

Growing Profit Margin: HZNP's current net profit margins (22.9%) are higher than last year (12.8%).


Past Earnings Growth Analysis

Earnings Trend: HZNP has become profitable over the past 5 years, growing earnings by 64% per year.

Accelerating Growth: HZNP's earnings growth over the past year (207.9%) exceeds its 5-year average (64% per year).

Earnings vs Industry: HZNP earnings growth over the past year (207.9%) exceeded the Biotechs industry 96.9%.


Return on Equity

High ROE: HZNP's Return on Equity (17.9%) is considered low.


Financial Health

How is Horizon Therapeutics's financial position?

Financial Health Score

5/6

Financial Health Score 5/6

  • Short Term Liabilities

  • Long Term Liabilities

  • Debt Level

  • Reducing Debt

  • Debt Coverage

  • Interest Coverage

Financial Position Analysis

Short Term Liabilities: HZNP's short term assets ($2.9B) exceed its short term liabilities ($825.2M).

Long Term Liabilities: HZNP's short term assets ($2.9B) do not cover its long term liabilities ($3.1B).


Debt to Equity History and Analysis

Debt Level: HZNP's net debt to equity ratio (19.2%) is considered satisfactory.

Reducing Debt: HZNP's debt to equity ratio has reduced from 157% to 53.3% over the past 5 years.

Debt Coverage: HZNP's debt is well covered by operating cash flow (48.8%).

Interest Coverage: HZNP's interest payments on its debt are well covered by EBIT (10.7x coverage).


Balance Sheet


Dividend

What is Horizon Therapeutics's current dividend yield, its reliability and sustainability?

Dividend Score

0/6

Dividend Score 0/6

  • Notable Dividend

  • High Dividend

  • Stable Dividend

  • Growing Dividend

  • Earnings Coverage

  • Future Dividend Coverage

Dividend Yield vs Market

Notable Dividend: Unable to evaluate HZNP's dividend yield against the bottom 25% of dividend payers, as the company has not reported any recent payouts.

High Dividend: Unable to evaluate HZNP's dividend yield against the top 25% of dividend payers, as the company has not reported any recent payouts.


Stability and Growth of Payments

Stable Dividend: Insufficient data to determine if HZNP's dividends per share have been stable in the past.

Growing Dividend: Insufficient data to determine if HZNP's dividend payments have been increasing.


Earnings Payout to Shareholders

Earnings Coverage: Insufficient data to calculate payout ratio to determine if its dividend payments are covered by earnings.


Cash Payout to Shareholders

Cash Flow Coverage: Unable to calculate sustainability of dividends as HZNP has not reported any payouts.


Discover strong dividend paying companies

Management

How experienced are the management team and are they aligned to shareholders interests?

5.5yrs

Average management tenure


CEO

Tim Walbert (54 yo)

13.92yrs

Tenure

US$21,353,458

Compensation

Mr. Timothy P. Walbert, also known as Tim, had been the Chairman of the Board at Exicure, Inc. since April 2020 until February 4, 2022 and had been its Independent Director since July 22, 2019 until Februa...


CEO Compensation Analysis

Compensation vs Market: Tim's total compensation ($USD21.35M) is above average for companies of similar size in the US market ($USD13.26M).

Compensation vs Earnings: Tim's compensation has been consistent with company performance over the past year.


Leadership Team

Experienced Management: HZNP's management team is seasoned and experienced (5.5 years average tenure).


Board Members

Experienced Board: HZNP's board of directors are considered experienced (8.1 years average tenure).


Ownership

Who are the major shareholders and have insiders been buying or selling?


Insider Trading Volume

Insider Buying: HZNP insiders have only sold shares in the past 3 months.


Recent Insider Transactions

Ownership Breakdown

Dilution of Shares: Shareholders have been diluted in the past year, with total shares outstanding growing by 2.3%.


Top Shareholders

Company Information

Horizon Therapeutics Public Limited Company's employee growth, exchange listings and data sources


Key Information

  • Name: Horizon Therapeutics Public Limited Company
  • Ticker: HZNP
  • Exchange: NasdaqGS
  • Founded: 2005
  • Industry: Biotechnology
  • Sector: Pharmaceuticals & Biotech
  • Implied Market Cap: US$20.326b
  • Shares outstanding: 229.88m
  • Website: https://www.horizontherapeutics.com

Number of Employees


Location

  • Horizon Therapeutics Public Limited Company
  • 70 St. Stephen’s Green
  • Dublin
  • Co. Dublin
  • 2
  • Ireland

Listings


Company Analysis and Financial Data Status

All financial data provided by Standard & Poor's Capital IQ.
DataLast Updated (UTC time)
Company Analysis2022/05/19 00:00
End of Day Share Price2022/05/19 00:00
Earnings2022/03/31
Annual Earnings2021/12/31


Unless specified all financial data is based on a yearly period but updated quarterly. This is known as Trailing Twelve Month (TTM) or Last Twelve Month (LTM) Data. Learn more here.